Scholar Rock Holding SRRK 深 滬
等待開盤 09-24 09:30:00 美东时间
49.85
-1.340
-2.62%
華盛通- 最 高51.735
- 今 開51.19
- 成交量 249.26万股
- 最 低 49.25
- 昨 收 51.19
- 總市值 60.71亿
- 52周最高 61.76
- 市盈率 靜 --
- 換手率 2.05%
- 52周最低 27.07
- 委 比 -8.68%
- 總股本 1.22亿
- 歷史最高 70.00
- 量 比 0.73
- 振 幅 4.85%
- 歷史最低 4.325
- 每 手 1
- 風險率 7.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
美股周涨跌榜 | AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%
AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%，与礼来TuneLab达成合作；FPS升24%，2027财年业绩指引大超预期>>
09-20 09:30
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG cut the price target for Exodus Movement Inc (NYSE:EXOD) from $16 to $12. BTIG analyst Andrew Harte maint...
09-15 20:41
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
09-14 20:45
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Scholar Rock Holding (SRRK) surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal muscular atrophy. Isembyld, also known as...
09-14 01:32
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug des...
09-02 20:03
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facility Company is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026 Prescription Drug User Fee Act (PDUFA) date; robust supply of apitegromab c...
08-21 21:11
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
